Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Prostate cancer

Johnson & Johnson
Regional

FDA Clears Breakthrough Precision Combo for Aggressive Prostate Cancer

December 18, 2025December 18, 2025 - by Timothy Alexander

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has approved an expanded indication for AKEEGA, clearing the first FDA-approved precision medicine combination for …

FDA Clears Breakthrough Precision Combo for Aggressive Prostate Cancer Read More

Teleflex Incorporated
Products and Services

Teleflex Launches Barrigel™ Rectal Spacer in Japan Following Regulatory Approval

August 21, 2025August 20, 2025 - by Timothy Alexander

WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has announced the commercial launch of its Barrigel™ rectal spacer in Japan, marking a significant step in the company’s international expansion strategy. The …

Teleflex Launches Barrigel™ Rectal Spacer in Japan Following Regulatory Approval Read More
National Comprehensive Cancer Network
Cancer

Study Finds Most Prostate Cancer Patients Following NCCN Guidelines Live Long, Healthy Lives

July 13, 2025July 12, 2025 - by Timothy Alexander

PLYMOUTH MEETING, PA — New research published in the July 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network offers encouraging news for men diagnosed with nonmetastatic prostate cancer. …

Study Finds Most Prostate Cancer Patients Following NCCN Guidelines Live Long, Healthy Lives Read More

Teleflex Incorporated
Health / Medical

Teleflex Launches Awareness Initiatives for Men’s Health Month

June 12, 2025June 11, 2025 - by Timothy Alexander

WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has introduced two major initiatives during Men’s Health Month to highlight the challenges men face with benign prostatic hyperplasia (BPH) and the importance …

Teleflex Launches Awareness Initiatives for Men’s Health Month Read More
National Comprehensive Cancer Network
Regional

NCCN Funds Research to Address Side Effects of PARP Inhibitors in Prostate Cancer Treatment

December 23, 2024December 22, 2024 - by Timothy Alexander

PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has announced funding for a new project aimed at improving the management of side effects caused …

NCCN Funds Research to Address Side Effects of PARP Inhibitors in Prostate Cancer Treatment Read More

National Comprehensive Cancer Network
Cancer / Regional

NCCN Funds Research to Address Side Effects of PARPi Treatment in Prostate Cancer

December 16, 2024December 15, 2024 - by Timothy Alexander

PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has announced funding for a new project aimed at improving management of side effects caused by poly …

NCCN Funds Research to Address Side Effects of PARPi Treatment in Prostate Cancer Read More

Trending News

  • Thefts, Assault Call, Sex Crime Report Mark Turbulent Day for Wyomissing Police

  • Gun, Ammo Seized After Shots Fired Report Sparks Wilmington Arrest

  • Overnight Lane Closures Return to U.S. 30 as Bypass Repairs Press On

  • Lane Closures Grip Busy Route 202 Intersection as PennDOT Pushes Safety Fix

  • $1B Saved in One Year: Pa. Treasury Posts Stunning Growth in 529, ABLE

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Police News

Thefts, Assault Call, Sex Crime Report Mark Turbulent Day for Wyomissing Police

January 18, 2026January 18, 2026

Daiquan Reams

Gun, Ammo Seized After Shots Fired Report Sparks Wilmington Arrest

January 18, 2026January 18, 2026

Police News

$4,100 Retail Theft and Human Trafficking Sting Mark Busy Wyomissing Day

January 17, 2026January 17, 2026

Copyright © 2026 MyChesCo.